SETD2 has been shown to interact with p53′s transactivation domain (TAD) [15], which binds HDM2, an ubiquitin-protein ligase that inhibits the tumor suppressor’s activity and promotes its degradation. This evidence concerns the gene SETD2 and neoplasm.